Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoniazid + rifapentine + moxifloxacin + pyrazinamide
- Development stage
- Unknown
- Lead developer
- Shanghai Public Health Clinical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
2HPMZ + 2HPM (also known as 2HPMZ/2HPM) is a four-month, short-course antibiotic combination regimen investigated for the treatment of drug-susceptible pulmonary tuberculosis. The regimen consists of an intensive phase of two months of daily isoniazid (H), rifapentine (P), moxifloxacin (M), and pyrazinamide (Z), followed by a continuation phase of two months of daily isoniazid, rifapentine, and moxifloxacin. This regimen is designed as a shorter alternative to the standard six-month 2HRZE/4HR treatment. The components work synergistically: isoniazid inhibits mycolic acid synthesis; rifapentine is a rifamycin-class RNA polymerase inhibitor; moxifloxacin is a fluoroquinolone that inhibits DNA gyrase and topoisomerase IV; and pyrazinamide is active against semi-dormant bacilli. It is currently being evaluated in clinical trials, including studies sponsored by the Shanghai Public Health Clinical Center specifically for HIV-infected patients with low CD4 counts.
- Other names
- isoniazid + rifapentine + moxifloxacin + pyrazinamide
02
Targets
RpsA (30S ribosomal protein S1)InhA (Enoyl-[acyl-carrier-protein] reductase [NADH])rpoB (DNA-directed RNA polymerase subunit beta)DNA gyrase (Mycobacterium tuberculosis)
Beyond the preview
Go deeper on isoniazid + rifapentine + moxifloxacin + pyrazinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoniazid + rifapentine + moxifloxacin + pyrazinamide.